bioMérieux Extends Portfolio of Full Micriobiology Lab Automation solutions at ASM General Meeting

At a time when skilled microbiology resources are dwindling and economic pressures and cost cutting objectives for hospitals are increasing, bioMérieux will unveil several new solutions: Myla™: revolutionary new informatics solution to improve lab workflow, information management and instrument connectivity.

NucliSENS® EasyQ® MRSA: molecular based test for MRSA, one of the most prevalent multi-drug resistant bacteria. VITEK® 2 PC 5.01: clinical information software that enables more rapid and informative antibiotic susceptibility testing results (AST) for clinicians. chromIDTM VRE and MRSA: chromogenic culture media for leading causes of HAI. Mass Spectrometry: new solution for bacterial identification.

For more information on bioMerieux’s full line of solutions, visit www.biomerieux-usa.com/whatsnew.

bioMérieux’s chief executive officer, Stéphane Bancel, will present Myla™ for the first time in North America on Monday, May 24. Myla is an innovative laboratory informatics solution that consolidates and transforms microbiology laboratory data into actionable information for patient treatment decisions – while optimizing lab productivity.

“Time-to-treatment is critical when dealing with today’s multi-drug resistant organisms,” said Bancel. “bioMérieux’s new informatic solution, Myla, will transform the way microbiologists work today, significantly improving operational efficiency and making the most relevant information readily available to clinicians so they can take action rapidly. This latest innovation is yet another testimony to our commitment to deliver full microbiology laboratory automation,” he added.

bioMérieux is driving the fight against healthcare-associated infections, broadening its range of microbiology solutions to include NucliSENS® EasyQ® MRSA, a molecular assay for the rapid screening of methicillin-resistant Staphylococcus aureus, one of the most pervasive sources for high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.¹ This new assay, which is soon to be submitted for FDA clearance, is CE marked and already available in Europe where it is used for MRSA colonization screening. With NucliSENS EasyQ MRSA and chromID™ MRSA, bioMérieux will offer customers the most flexible and complete solution to effectively manage MRSA, spanning manual and automated techniques.

bioMérieux will also showcase its new mass spectrometry solution featuring a platformfor MALDI-ToF based identification, from Japanese leader, Shimadzu, as well as an extensive library of microorganisms, recently acquired from AnagnosTec, compatible with the Shimadzu system.

In conjunction with the events occurring during the ASM General Meeting, the company will host a FutureLab Symposium, May 24 at the San Diego Marriott Hotel and Marina. The symposium will be moderated by Joel Mortsensen, Ph.D., Cincinnati Children’s Hospital, and promises to stimulate the audience with new approaches, experiences and visions for creating a microbiology lab of the future. Along with Dr. Mortensen, the symposium will feature industry experts including:

• Joseph Campos, Ph.D. – Director, Microbiology and Molecular Laboratories and Laboratory Informatics, Children’s National Medical Center
• Linda Bruno, M.A., MT (ASCP) – Associate Administrative Director, University of Illinois Medical Center

bioMérieux will exhibit at booth #134 during the 2010 ASM General meeting.

¹ Marchaim D. et al. The burden of methicillin-resistance Staphylococcus aureus infections on patients hospitalized in the US. 46th ICAAC meeting, San Francisco (USA), September 28, 2006 Abstract K-791

About bioMérieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached €1.223 billion with 85% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

Contacts

bioMérieux
Allan Mohess
Tel: + 1 919-620-2937
allan.mohess@biomerieux.com

Fleishman-Hillard
Kim Mays
Tel: + 1 216-928-3459
kimberly.mays@fleishman.com